IPS HEART Granted Orphan Drug Designation in the EU for Becker Muscular Dystrophy
While we are grateful to the dozens of BMD patients who have emailed us directly for information on our upcoming clinical trials, to date we are initially focused on advancing GIVI-MPCs clinically in a Phase I/II DMD clinical trial until we can secure additional partners to help us advance clinically in BMD. IPS HEART is currently under formal CDA with certain large pharmaceutical companies for a possible partnership that will also allow us to advance GIVI-MPCs clinically in BMD as we have already successfully produced GIVI-MPCs via large scale suspension based bioreactor manufacturing which can supply the large patient population in the future.
About IPS HEART/GIVI-MPCs
GIVI-MPCs derived from pluripotent stem cells form new skeletal muscle with 100% full-length human dystrophin for DMD and BMD. IPS HEART has also developed ISX-9-CPCs, a human iPSC-derived cardiac therapy for treatment of Duchenne cardiomyopathy and heart failure that develops new heart muscle.
About Becker & Duchenne Muscular Dystrophy
BMD is a muscular disease and DMD is a fatal neuromuscular disease.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 minutes ago
- Business Wire
RXST INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges RxSight as well as certain of RxSight's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the RxSight class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or of Robbins Geller by calling 800/449-4900 or via e-mail at info@ Lead plaintiff motions for the RxSight class action lawsuit must be filed with the court no later than September 22, 2025. CASE ALLEGATIONS: RxSight is a commercial-stage medical technology company that engages in the research and development, manufacture, and sale of light adjustable intraocular lenses ('LAL') used in cataract surgery. The RxSight class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) RxSight was experiencing 'adoption challenges' and/or structural issues resulting in declines in sales and utilization; (ii) defendants had overstated the demand for RxSight's products; and (iii) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025. The RxSight class action lawsuit further alleges that on July 8, 2025, RxSight reported preliminary second quarter of 2025 financial results, revealing significant declines in Light Delivery Device ('LDD') sales, LAL utilization, and overall revenue. RxSight also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint, and RxSight's CEO, defendant Ronald Kurtz, disclosed that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall,' according to the complaint. The RxSight class action lawsuit alleges that on this news, the price of RxSight stock fell nearly 38%. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired RxSight securities during the class period to seek appointment as lead plaintiff in the RxSight class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the RxSight class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the RxSight class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the RxSight class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Business Wire
4 minutes ago
- Business Wire
Phenom Earns Spot as SaaS Awards 2025 Finalist for Intelligence and Automation Platform
PHILADELPHIA--(BUSINESS WIRE)-- Phenom, an applied AI company that helps organizations hire faster, develop better and retain longer, has been named a finalist in The 2025 SaaS Awards for its intelligence and automation platform. 'SaaS solutions are becoming increasingly sophisticated, and standing out from the crowd can be a tough task. Phenom, and their fellow finalists, have done exceptionally well in reaching this stage,' said CEO of The Cloud Awards, James Williams. Share CEO of The Cloud Awards, James Williams, said: 'We're pleased to confirm the finalists in this year's SaaS Awards. This year features a particularly competitive field of nominations, giving our judges a tough, yet rewarding, task in turning our shortlist into an exclusive range of finalists. 'Driven by the continued investment and evolution of AI within the industry, SaaS solutions are becoming increasingly sophisticated, and standing out from the crowd can be a tough task. Phenom, and their fellow finalists, have done exceptionally well in reaching this stage, and we wish them well as our judges go on to select this year's winners.' Building on its recent recognition as a Top 25 AI Company by the Software Report and Best Cloud HR/HRMS Solution in The 2024/25 Cloud Awards program, Phenom continues to earn industry acclaim for its bold innovation that unifies rather than fragments the entire talent experience for all stakeholders through a single experience-first platform. The comprehensive solution addresses critical HR challenges through advancements in data standardization, domain-specific AI, scalability, real-time personalization, conversational and agentic AI, compliance, and seamless integration with existing HR systems. In 2025, Phenom introduced breakthrough innovations including X+ Ontologies, X+ Agent Studio, and industry-specific X+ Agents that bridge the gap between business strategy and HR execution. These purpose-built agents streamline essential processes across industries like healthcare, retail, financial services, and manufacturing — from candidate sourcing to talent development — while transforming unstructured enterprise data into actionable insights. 'The real test of AI in HR isn't what it can do in a demo — it's how real companies are turning the messy, unstructured reality of their enterprise data and systems into a seamless experience across their entire talent ecosystem,' said John Harrington, Sr. Director, Product Marketing at Phenom. 'Our customers are already seeing the impact of this transformation, and this recognition further validates that our approach is working.' Learn why Phenom's industry-specific AI and automation continues to earn accolades. Tune in to Industry Week July 28 through August 1 live or on demand. Register at With Phenom, candidates find and choose the right job faster, employees develop their skills and evolve, recruiters become wildly productive, talent marketers engage with extreme efficiency, talent leaders optimize hiring and onboarding processes, managers build stronger-performing teams, HR aligns employee development with company goals, and HRIT easily integrates existing HR tech to create a holistic infrastructure. The SaaS Awards recognizes the organizations that are leading the way in the software-as-a-service industry – from specialized 'vertical SaaS' solutions through to broader services for enterprise or SME businesses. The program received entries from organizations of all sizes from across the globe, including the USA and Canada, the UK and Europe, the Middle East, and APAC. About Phenom Phenom has a purpose of helping a billion people find the right work. Through AI-powered talent experiences, employers use Phenom to hire and onboard employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, talent marketers, talent leaders, hiring managers, HR and HRIT — empowering diverse and global enterprises with innovative products including Phenom X+ Agentic AI and Generative AI, Career Site, Chatbot, CMS, Talent CRM, X+ Screening, Automated Interview Scheduling, Interview Intelligence, Talent Experience Engine, Campaigns, University Recruiting, Contingent Talent Hiring, Onboarding, Talent Marketplace, Workforce Intelligence, Career Pathing, Gigs, Mentoring, and Referrals. Phenom has earned accolades including: Inc. 5000's fastest-growing companies (5 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), 11 Brandon Hall 'Excellence in Technology' awards including Gold for 'Best Advance in Generative AI for Business Impact,' Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), The Cloud Awards 2025/2024, The A.I. Awards 2024, and a regional Timmy Award for launching and optimizing (2020). Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
Business Wire
4 minutes ago
- Business Wire
Ecore International Appoints Jeff Coté as President & Chief Operating Officer
LANCASTER, Pa.--(BUSINESS WIRE)--Ecore International, a global leader in circularity, transforming reclaimed rubber materials into innovative, high-performance products that drive sustainability and reduce environmental impact, today announced that Jeff Coté has joined Ecore as President and Chief Operating Officer (COO). Coté joins Ecore with over two decades of executive leadership experience, most recently at Sensata Technologies, where he served as Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer, navigating complex, rapidly changing markets and delivering strong results. As President and COO, Coté will oversee the company's day-to-day operations and lead the execution of strategic initiatives, including opportunities for market expansion through additional services and offerings across Ecore's various lines of business and acquisitions. He will also sharpen the company's customer focus, drive process and performance improvements, and support the integration of Ecore's growing roster of acquisitions, such as the recently completed acquisition of HTI Recycling. 'Jeff is a great addition to the Ecore family, and he will be instrumental as we continue to accelerate growth across our business. His exceptional leadership capabilities, commitment to operational excellence and proven track record of guiding companies through significant periods of expansion align well with our vision of ridding the planet of rubber waste through our mission of circularity," said Art Dodge, Chairman and CEO of Ecore International. Coté added, 'I am thrilled to join the Ecore team at this exciting time. I believe strongly in Ecore's circularity vision and am looking forward to collaborating with the team as we work to further grow the business and execute on Ecore's mission at scale.' For more information about Ecore, visit About Jeff Coté Jeff Coté is President and Chief Operating Officer of Ecore International. He has been on the board of directors of Trinseo since May 2014. Jeff formerly served as President and Chief Executive Officer, and member of the Board of Directors, of Sensata Technologies Holding plc (NYSE:ST) from 2020 to 2024. He joined Sensata as Senior Vice President and Chief Financial Officer in 2007 and served in various roles during his tenure, including Executive Vice President of its Global Sensing Solutions business. From March 2005 to December 2006, he was Chief Operating Officer of the law firm Ropes & Gray. From January 2000 to March 2005, Jeff was Chief Operating, Financial and Administrative Officer of Digitas. Previously he worked for Ernst & Young LLP from 1989 until 1997. Jeff is a Certified Public Accountant and brings significant management, capital markets and accounting experience to Ecore. About Ecore International Ecore is a transformational rubber circularity company. Built on a legacy that began in 1871, we are leading our industry's circular economy founded on the magic of rubber—a material with a proven past and the potential to reinvent the future. Like rubber itself, we are constantly flexing and finding new challenges to solve, new performance properties to engineer, and new uses for this infinitely reusable material. Headquartered in Lancaster, Pa., Ecore serves customers in more than 75 countries, designing innovative technologies and solutions for many industries, including rubber reclamation services, rubber materials, commercial and performance flooring, play surfacing, industrial components, transportation, and agricultural products. Ecore brands include Ecore Athletic, ECOsurfaces, Centaur, QT Sound Insulation, A-Turf, Surface America, SpectraTurf, Ecore Industrial, Ecore Reclamation, Ecore Materials, itsTRU ® Technology, and TRUcircularity™. Learn more at
